Prostate specific antigen complexed to α‐1‐antichymotrypsin in patients with intermediate prostate specific antigen levels
Authors:
- Takashi SaikaTSTakashi Saika
- for the Okayama Urological Cancer Collaborating GroupFGfor the Okayama Urological Cancer Collaborating Group
Abstract
BACKGROUND: The authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (PSA) complexed to α‐1‐antichymotrypsin (PSA‐ACT) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (BPH), especially among patients with intermediate PSA levels.METHODS: Between December 1999 and August 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum PSA levels between 4.1 ng/mL and 20.0 ng/mL. The serum samples were assayed by using kits that were designed specifically for measuring serum PSA, PSA‐ACT, and free PSA levels. The clinical values of PSA, PSA‐ACT, the free PSA to total PSA ratio (F/T ratio), the free PSA to PSA‐ACT ratio, PSA density (PSAD), and PSA‐ACT density (ACTD) were compared by using receiver operating characteristic (ROC) curve analysis.RESULTS: Biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. ROC analysis demonstrated that the area under the curve (AUC) for PSA‐ACT was greater than that for total PSA and was equivalent to that for the F/T ratio in both groups of patients (PSA ranges of 4.1–20.0 ng/mL and 4.1–10.0 ng/mL, respectively). The AUC for the ACTD was greater than the AUC for the PSAD and had the highest value of all parameters.CONCLUSIONS: The measurement of PSA‐ACT represents an alternative to the use of total and free PSA. The ACTD value is the most useful for discriminating between BPH and prostate carcinoma. Cancer 2002;94:1685–91. © 2002 American Cancer Society.DOI 10.1002/cncr.10377Keywords
This publication has 25 references indexed in Scilit:
- Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer DiagnosisEuropean Urology, 2001
- Determination of prostate-specific antigen complexed to alpha2-macroglobulin in serum increases the specificity of free to total PSA for prostate cancerUrology, 2000
- COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCERJournal of Urology, 2000
- Prostate–Specific Antigen Complexed to α1–Antichymotrypsin in the Early Detection of Prostate CancerEuropean Urology, 2000
- Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and RatiosJournal of Urology, 1995
- Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostateUrology, 1994
- Serum Prostate-Specific Antigen in a Community-Based Population of Healthy MenJAMA, 1993
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Prostate‐specific antigen and prostate gland volume: Correlation and clinical applicationJournal of Clinical Laboratory Analysis, 1990
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982